Results 191 to 200 of about 352,777 (258)
A gene-specific RNA enrichment protocol for nanopore direct-RNA sequencing. [PDF]
Dyrendalsli MB, Løkke C, Einvik C.
europepmc +1 more source
New insights into the molecular evolution of Metazoan Peroxiredoxins. [PDF]
Bakiu, Rigers, Santovito, Gianfranco
core
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena +15 more
wiley +1 more source
Corrigendum to "Exosomes as novel tools for renal cell carcinoma therapy, diagnosis, and prognosis" [Heliyon Volume 10, Issue 12, June 30, 2024, Article e32875]. [PDF]
Razavinia A +8 more
europepmc +1 more source
Translational cancer research and its implementation through competitively selected Comprehensive Cancer Centers across Europe should be the primary policy focus for addressing the increasing cancer burden in Europe and counteract the present main strategy to convert cancer to a chronic disease.
Manuel Heitor +2 more
wiley +1 more source
A population-scale multi-omics blueprint of immune gene regulation. [PDF]
Ventura AB, Deligio L, Volpe G.
europepmc +1 more source
Insights into a long life without cancer: The case of the bowhead whale
Long‐lived, large‐bodied organisms have evolved powerful anticancer mechanisms that preserve cellular and tissue integrity across extended lifespans. A recent study by Firsanov et al. shows that greater genome stability is a key factor underlying the remarkable longevity and cancer resistance of one such species, the bowhead whale.
Inés Paniagua, Johanna A. Joyce
wiley +1 more source
Editorial: Exploring epigenetic mechanisms in cancer. [PDF]
Sherif ZA, Ressom HW, Ogunwobi OO.
europepmc +1 more source
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata +10 more
wiley +1 more source

